Aptevo Therapeutics (APVO) Highlights APVO603

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. DPZ
2. NVDA
3. BAC
4. DRS
5. GS
6. UNH
7. ORCL
8. AVAV
9. ACI
10. LMT

Go back to Aptevo Therapeutics (APVO) Highlights APVO603

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

March 18, 2025 8:07 AM EDT

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action

SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ: APVO), a leader in the development of novel bispecific antibodies for cancer treatment, based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies provided an overview of solid tumor anti-cancer compound APVO603, currently in preclinical development for the treatment of solid tumors. APVO603 is a novel bispecific antibody designed to... More